HPV-associated cancers among people living with HIV: nationwide population-based retrospective cohort study 2004–21 in Estonia
European Journal of Public Health · 01.12.2024 · 34 (6) · 1199-1204
DOI: 10.1093/eurpub/ckae152 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift European Journal of Public Health, online erschienen am 08.10.2024. Verfasst von Anna Tisler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia. Hauptthemen laut MEDLINE: HIV Infections, Papillomavirus Infections, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norway Grants and Estonian Research Council, EMP416, EEA.
Abstract (Originalsprache)
Cancers represent the primary cause of mortality among people living with HIV (PLWH). However, comprehensive nationwide data regarding cancer incidence remains limited. Our objective was to evaluate the incidence rates of cancers, particularly those associated with human papillomavirus (HPV), within a nationwide study cohort. Using data from the Estonian Health Insurance Fund and the National Cancer Registry from 2004 to 2021, we calculated standardized incidence ratios (SIRs) for various cancer types among PLWH to compare to the general population with special emphases on HPV-associated cancers. A total of 7011 individuals (65.7% men) diagnosed with HIV were identified. HPV-associated cancers accounted for 21.4% of all incident cancer cases among PLWH. SIRs for HPV-associated cancers were 3.7 [95% confidence interval (CI) 2.2–6.2] among men living with HIV (MLWH) and 5.7 (95% CI 4.0–7.9) among women living with HIV (WLWH). In MLWH, the highest SIRs were for penile 12.5 (95% CI 4.0–38.7), followed by oropharyngeal 3.6 (95% CI 1.7–7.6) and anal–rectal cancers 2.7 (95% CI 1.1–6.4) in comparison to the general population. In WLWH, an increased incidence of cervical (SIR = 5.8, 95% CI 3.9–8.5), oropharyngeal (SIR = 6.1, 95% CI 1.5–24.3), and anal–rectal (SIR = 3.6, 95% CI 1.2–11.2) cancers was observed. A significantly increased risk of AIDS-defining and non-AIDS-defining cancers is reported. We demonstrate a substantially heightened risk of HPV-associated cancers among PLWH compared to the general population, underscoring the imperative for intensified screening and scaled-up vaccination along with improvement in adherence to antiretroviral therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
- CIC-P INSERM 1432, Centre Hospitalier Universitaire de Dijon, Dijon, France.
- Department of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY, United States.
- Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
ORCID-Profile: Anna Tisler, Anneli Uusküla
Förderung
- Norway Grants and Estonian Research Council
- EMP416
- EEA
- European Economic Area
- Estonian Research Council
Zitieren
APA
Tisler, A., Toompere, K., Bardou, M., Diaz, J., Orumaa, M., & Uusküla, A. (2024). HPV-associated cancers among people living with HIV: nationwide population-based retrospective cohort study 2004–21 in Estonia. European Journal of Public Health, 34(6), 1199-1204. https://doi.org/10.1093/eurpub/ckae152
Vancouver
Tisler A, Toompere K, Bardou M, Diaz J, Orumaa M, Uusküla A. HPV-associated cancers among people living with HIV: nationwide population-based retrospective cohort study 2004–21 in Estonia. European Journal of Public Health. 2024;34(6):1199-1204. doi:10.1093/eurpub/ckae152
BibTeX
@article{Tisler2024,
author = {Tisler, Anna and Toompere, Karolin and Bardou, Marc and Diaz, Jose and Orumaa, Madleen and Uusküla, Anneli},
title = {HPV-associated cancers among people living with HIV: nationwide population-based retrospective cohort study 2004–21 in Estonia},
journal = {European Journal of Public Health},
year = {2024},
volume = {34},
number = {6},
pages = {1199--1204},
doi = {10.1093/eurpub/ckae152}
}
EUVIMED